Parkinson's disease (PD) is a progressive disease of the brain that causes tremors and muscle stiffness and slows movements. It develops when neurons (brain cells) in a specific part of the brain stop working properly and are lost over time. These neurons produce an important chemical called dopamine. Dopamine is used by the brain to send messages between brain areas to control movement. At some point, the brain can no longer produce enough dopamine to properly control movement. 1, 2
Is there a cure for Parkinson's disease??
Currently, there is no cure for Parkinson's disease. Existing treatments aim to help patients manage symptoms.
What are the latest approved treatments for Parkinson's disease?
Several drugs have been approved for the treatment of Parkinson's disease. Here are some of the medications available for Parkinson's disease:
Nuplazid (pimavanserin) 3, 4
Nuplazid (pimavanserin) is the first drug approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Nuplazid (pimavanserin) was launched on 29. April 2016 by the Food and Drugs Administration (FDA) (USA) for the treatment of patients with hallucinations. Delusions admitted in connection with the psychosis of Parkinson's disease. Am 3. December 2020, the (FDA) approved an update to the prescribing information for Nuplazid (pimavanserin) that will allow the drug to be taken more easily by Parkinson's disease patients who have difficulty swallowing.
Ongentys (opicapone) 5, 6
Ongentys (opicapone) is a drug used to treat Parkinson's disease. It is indicated for the treatment of adult patients with Parkinson's disease. It is used as an add-on to levodopa/DOPA decarboxylase inhibitors (DDCI) (other medicines used to treat Parkinson's disease) in patients who have fluctuations in the control of their condition.
Opicapone was approved on 24. June 2016 by the European Medicines Agency (EMA) and on 24. April 2020 approved by the Food and Drug Administration (FDA) to treat patients with Parkinson's disease as an add-on therapy to levodopa/DOPA decarboxylase inhibitors (DDCI).
Nourianz/Nouriast (istradefylline) 7, 8, 9
Nourianz/Nouriast (istradefylline) is a drug for the treatment of "Off"-Episodes in patients with Parkinson's disease. The "Off"-Episodes in Parkinson's disease result in an increase in Parkinson's symptoms, such as tremor and difficulty walking, and are the result of low dopamine levels between doses of carbidopa/levodopa, and may be unpredictable and occur more frequently over time.
Nourianz/Nouriast (istradefylline) was approved by the Food and Drug Administration (FDA), U.S., on 27. August 2019 and approved by the Pharmaceuticals and Medical Devices Agency (PMDA), Japan, in June 2013.
Inbrija (levodopa) 10, 11, 12
Inbrija (levodopa) is an aromatic amino acid indicated for the treatment of Parkinson's disease. It is used to treat symptoms during the "off"-Phases (times when the patient has more difficulty moving) used while the patient is taking his or her usual treatment with a combination of carbidopa and levodopa. It does not replace regular carbidopa/levodopa therapy.
Inbrija (levodopa) was launched on 21. December 2018 by the Food and Drug Administration (FDA), U.S., and on 19. September 2019 approved by the European Medicines Agency (EMA), Europe, for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with regular carbidopa/levodopa medications.
If you have been diagnosed with Parkinson's disease and are trying to access a new drug for Parkinson's disease that is approved outside of your country of residence, we may be able to help you access this drug with the help of your treating physician. You can read more about the medications we can help you with and their price below:
Nuplazid 34mg (pimavanserin)
What are the experimental treatments for Parkinson's disease??
Several therapies are currently in clinical trials for the treatment of motor and non-motor symptoms, as well as treatments to prevent, slow or halt the progression of Parkinson's disease overall.
For a complete list of experimental treatments for Parkinson's disease, visit the Michael J Fox Organization website here.
Why a Parkinson's treatment with TheSocialMedwork?
TheSocialMedwork is registered in The Hague with the Dutch Ministry of Health (registration number 6730 BEM) as an independent drug intermediary. We have helped patients from over 85 countries gain access to thousands of medications. With a prescription from your treating physician, you can rely on our team of experts to guide you safely and legally to access a new medication for Parkinson's disease. If you or someone you know is looking to access a medication that is not yet approved where they live, we can support you. Contact us for more information.
Disclaimer: This article is not intended to influence or interfere with treatment by your treating physician. Please do not make any changes to your treatment without first consulting your treating physician. This article is not intended to diagnose or treat disease or to influence treatment options. TheSocialMedwork compiles and updates the information on this page with the greatest possible care. However, TheSocialMedwork does not guarantee for the correctness. Completeness of the information provided on this page.